News

Article

Medherant Receives Grant from Innovate UK for Transdermal Patch Manufacturing

Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.

Medherant, a developer of innovative transdermal drug delivery treatments for pain and central nervous system diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK, the company announced in an Oct. 3, 2018 press release. The grant will enable the company to buy equipment and move forward with its plans to extend its pilot-scale manufacture of patches formulated with its unique TEPI Patch technology to GMP manufacture for clinical trials. 

The patent-protected patch technology enables the development of drug-in-adhesive patch products with better adhesion and more efficient delivery of drugs through the skin over a prolonged period. Medherant's first product, an ibuprofen TEPI Patch, is in Phase I clinical development with initial results expected in Q4 2018. Medherant's business model is to develop products to then out-license to established pharmaceutical companies for commercialization.

Medherant recently installed its own pilot-scale patch manufacturing plant and has successfully produced non-GMP patches of the ibuprofen TEPI Patch. The company has also produced patches for third parties interested in assessing the suitability of the TEPI technology for their drugs. Medherant’s high-throughput permeation assessment process rapidly identifies formulations that meet the target drug release profile, enabling the creation of candidate patch formulations in only two to three months.

Source: Medherant

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content